The technical feasibility of an image-guided intensity-modulated radiotherapy (IG-IMRT) to perform a hypofractionated schedule in terms of toxicity and local control for patients with locally advanced or recurrent pancreatic cancer
<p>Abstract</p> <p>Background</p> <p>The purpose of this study was to evaluate the technical feasibility of an image-guided intensity modulated radiotherapy (IG-IMRT) using involved-field technique to perform a hypofractionated schedule for patients with locally advance...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2012-12-01
|
| Series: | Radiation Oncology |
| Subjects: | |
| Online Access: | http://www.ro-journal.com/content/7/1/203 |
| _version_ | 1830221923096723456 |
|---|---|
| author | Son Seok Song Jin Choi Byung Kang Young-nam Lee Myung Kang Ki Jang Hong |
| author_facet | Son Seok Song Jin Choi Byung Kang Young-nam Lee Myung Kang Ki Jang Hong |
| author_sort | Son Seok |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>The purpose of this study was to evaluate the technical feasibility of an image-guided intensity modulated radiotherapy (IG-IMRT) using involved-field technique to perform a hypofractionated schedule for patients with locally advanced or recurrent pancreatic cancer.</p> <p>Methods</p> <p>From May 2009 to November 2011, 12 patients with locally advanced or locally recurrent pancreatic cancer received hypofractionated CCRT using TomoTherapy Hi-Art with concurrent and sequential chemotherapy at Seoul St. Mary’s Hospital, the Catholic University of Korea. The total dose delivered was 45 Gy in 15 fractions or 50 Gy in 20 fractions. The target volume did not include the uninvolved regional lymph nodes. Treatment planning and delivery were performed using the IG-IMRT technique. The follow-up duration was a median of 31.1 months (range: 5.7-36.3 months).</p> <p>Results</p> <p>Grade 2 or worse acute toxicities developed in 7 patients (58%). Grade 3 or worse gastrointestinal and hematologic toxicity occurred in 0% and 17% of patients, respectively. In the response evaluation, the rates of partial response and stable disease were 58% and 42%, respectively. The rate of local failure was 8% and no regional failure was observed. Distant failure was the main cause of treatment failure. The progression-free survival and overall survival durations were 7.6 and 12.1 months, respectively.</p> <p>Conclusion</p> <p>The involved-field technique and IG-IMRT delivered via a hypofractionated schedule are feasible for patients with locally advanced or recurrent pancreatic cancer.</p> |
| first_indexed | 2024-12-18T08:35:05Z |
| format | Article |
| id | doaj.art-b82687e7f773430393f6f1492de55954 |
| institution | Directory Open Access Journal |
| issn | 1748-717X |
| language | English |
| last_indexed | 2024-12-18T08:35:05Z |
| publishDate | 2012-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Radiation Oncology |
| spelling | doaj.art-b82687e7f773430393f6f1492de559542022-12-21T21:14:21ZengBMCRadiation Oncology1748-717X2012-12-017120310.1186/1748-717X-7-203The technical feasibility of an image-guided intensity-modulated radiotherapy (IG-IMRT) to perform a hypofractionated schedule in terms of toxicity and local control for patients with locally advanced or recurrent pancreatic cancerSon SeokSong JinChoi ByungKang Young-namLee MyungKang KiJang Hong<p>Abstract</p> <p>Background</p> <p>The purpose of this study was to evaluate the technical feasibility of an image-guided intensity modulated radiotherapy (IG-IMRT) using involved-field technique to perform a hypofractionated schedule for patients with locally advanced or recurrent pancreatic cancer.</p> <p>Methods</p> <p>From May 2009 to November 2011, 12 patients with locally advanced or locally recurrent pancreatic cancer received hypofractionated CCRT using TomoTherapy Hi-Art with concurrent and sequential chemotherapy at Seoul St. Mary’s Hospital, the Catholic University of Korea. The total dose delivered was 45 Gy in 15 fractions or 50 Gy in 20 fractions. The target volume did not include the uninvolved regional lymph nodes. Treatment planning and delivery were performed using the IG-IMRT technique. The follow-up duration was a median of 31.1 months (range: 5.7-36.3 months).</p> <p>Results</p> <p>Grade 2 or worse acute toxicities developed in 7 patients (58%). Grade 3 or worse gastrointestinal and hematologic toxicity occurred in 0% and 17% of patients, respectively. In the response evaluation, the rates of partial response and stable disease were 58% and 42%, respectively. The rate of local failure was 8% and no regional failure was observed. Distant failure was the main cause of treatment failure. The progression-free survival and overall survival durations were 7.6 and 12.1 months, respectively.</p> <p>Conclusion</p> <p>The involved-field technique and IG-IMRT delivered via a hypofractionated schedule are feasible for patients with locally advanced or recurrent pancreatic cancer.</p>http://www.ro-journal.com/content/7/1/203Unresectable pancreatic cancerHypofractionated radiotherapyImage-guidedIntensity-modulated radiotherapy |
| spellingShingle | Son Seok Song Jin Choi Byung Kang Young-nam Lee Myung Kang Ki Jang Hong The technical feasibility of an image-guided intensity-modulated radiotherapy (IG-IMRT) to perform a hypofractionated schedule in terms of toxicity and local control for patients with locally advanced or recurrent pancreatic cancer Radiation Oncology Unresectable pancreatic cancer Hypofractionated radiotherapy Image-guided Intensity-modulated radiotherapy |
| title | The technical feasibility of an image-guided intensity-modulated radiotherapy (IG-IMRT) to perform a hypofractionated schedule in terms of toxicity and local control for patients with locally advanced or recurrent pancreatic cancer |
| title_full | The technical feasibility of an image-guided intensity-modulated radiotherapy (IG-IMRT) to perform a hypofractionated schedule in terms of toxicity and local control for patients with locally advanced or recurrent pancreatic cancer |
| title_fullStr | The technical feasibility of an image-guided intensity-modulated radiotherapy (IG-IMRT) to perform a hypofractionated schedule in terms of toxicity and local control for patients with locally advanced or recurrent pancreatic cancer |
| title_full_unstemmed | The technical feasibility of an image-guided intensity-modulated radiotherapy (IG-IMRT) to perform a hypofractionated schedule in terms of toxicity and local control for patients with locally advanced or recurrent pancreatic cancer |
| title_short | The technical feasibility of an image-guided intensity-modulated radiotherapy (IG-IMRT) to perform a hypofractionated schedule in terms of toxicity and local control for patients with locally advanced or recurrent pancreatic cancer |
| title_sort | technical feasibility of an image guided intensity modulated radiotherapy ig imrt to perform a hypofractionated schedule in terms of toxicity and local control for patients with locally advanced or recurrent pancreatic cancer |
| topic | Unresectable pancreatic cancer Hypofractionated radiotherapy Image-guided Intensity-modulated radiotherapy |
| url | http://www.ro-journal.com/content/7/1/203 |
| work_keys_str_mv | AT sonseok thetechnicalfeasibilityofanimageguidedintensitymodulatedradiotherapyigimrttoperformahypofractionatedscheduleintermsoftoxicityandlocalcontrolforpatientswithlocallyadvancedorrecurrentpancreaticcancer AT songjin thetechnicalfeasibilityofanimageguidedintensitymodulatedradiotherapyigimrttoperformahypofractionatedscheduleintermsoftoxicityandlocalcontrolforpatientswithlocallyadvancedorrecurrentpancreaticcancer AT choibyung thetechnicalfeasibilityofanimageguidedintensitymodulatedradiotherapyigimrttoperformahypofractionatedscheduleintermsoftoxicityandlocalcontrolforpatientswithlocallyadvancedorrecurrentpancreaticcancer AT kangyoungnam thetechnicalfeasibilityofanimageguidedintensitymodulatedradiotherapyigimrttoperformahypofractionatedscheduleintermsoftoxicityandlocalcontrolforpatientswithlocallyadvancedorrecurrentpancreaticcancer AT leemyung thetechnicalfeasibilityofanimageguidedintensitymodulatedradiotherapyigimrttoperformahypofractionatedscheduleintermsoftoxicityandlocalcontrolforpatientswithlocallyadvancedorrecurrentpancreaticcancer AT kangki thetechnicalfeasibilityofanimageguidedintensitymodulatedradiotherapyigimrttoperformahypofractionatedscheduleintermsoftoxicityandlocalcontrolforpatientswithlocallyadvancedorrecurrentpancreaticcancer AT janghong thetechnicalfeasibilityofanimageguidedintensitymodulatedradiotherapyigimrttoperformahypofractionatedscheduleintermsoftoxicityandlocalcontrolforpatientswithlocallyadvancedorrecurrentpancreaticcancer AT sonseok technicalfeasibilityofanimageguidedintensitymodulatedradiotherapyigimrttoperformahypofractionatedscheduleintermsoftoxicityandlocalcontrolforpatientswithlocallyadvancedorrecurrentpancreaticcancer AT songjin technicalfeasibilityofanimageguidedintensitymodulatedradiotherapyigimrttoperformahypofractionatedscheduleintermsoftoxicityandlocalcontrolforpatientswithlocallyadvancedorrecurrentpancreaticcancer AT choibyung technicalfeasibilityofanimageguidedintensitymodulatedradiotherapyigimrttoperformahypofractionatedscheduleintermsoftoxicityandlocalcontrolforpatientswithlocallyadvancedorrecurrentpancreaticcancer AT kangyoungnam technicalfeasibilityofanimageguidedintensitymodulatedradiotherapyigimrttoperformahypofractionatedscheduleintermsoftoxicityandlocalcontrolforpatientswithlocallyadvancedorrecurrentpancreaticcancer AT leemyung technicalfeasibilityofanimageguidedintensitymodulatedradiotherapyigimrttoperformahypofractionatedscheduleintermsoftoxicityandlocalcontrolforpatientswithlocallyadvancedorrecurrentpancreaticcancer AT kangki technicalfeasibilityofanimageguidedintensitymodulatedradiotherapyigimrttoperformahypofractionatedscheduleintermsoftoxicityandlocalcontrolforpatientswithlocallyadvancedorrecurrentpancreaticcancer AT janghong technicalfeasibilityofanimageguidedintensitymodulatedradiotherapyigimrttoperformahypofractionatedscheduleintermsoftoxicityandlocalcontrolforpatientswithlocallyadvancedorrecurrentpancreaticcancer |